Personalized medication plans to reduce opioid use in acute musculoskeletal pain
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. Multicenter, Randomized, Controlled Study
NA · University Hospital, Rouen · NCT05905146
This study tests whether a personalized medication plan can help hospitalized patients with severe muscle and joint pain use fewer strong opioids and lower their risk of dependence compared to standard treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Rouen (other) |
| Locations | 3 sites (Lille and 2 other locations) |
| Trial ID | NCT05905146 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a personalized pharmaceutical plan (PPP) for patients hospitalized with acute non-cancer musculoskeletal pain. The PPP aims to inform and sensitize patients, potentially leading to a shorter duration of treatment with potent opioids and a reduced risk of dependence. Patients receiving the PPP will be compared to those managed under standard treatment protocols in rheumatology services. The study focuses on patients who are newly prescribed strong opioids or have had a prescription maintained for a limited duration.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients with acute non-cancer musculoskeletal pain who are starting or maintaining strong opioid treatment.
Not a fit: Patients with cancer, fibromyalgia, or those who have been on strong opioids for more than 30 days prior to inclusion will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer opioid prescribing practices and improved pain management for patients.
How similar studies have performed: While personalized medication plans are gaining attention, this specific approach to reducing opioid use in acute musculoskeletal pain is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient hospitalized in the rheumatology department * Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology * Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion Exclusion Criteria: * Patient with cancer or fibromyalgia already diagnosed at inclusion * Patient with poor French language skills * Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion * Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment * Patient already included in the study
Where this trial is running
Lille and 2 other locations
- CHU de Lille — Lille, France (RECRUITING)
- CHU de Nimes — Nîmes, France (RECRUITING)
- CHU de ROUEN — Rouen, France (RECRUITING)
Study contacts
- Principal investigator: Catherine CHENAILLER — University Hospital, Rouen
- Study coordinator: Catherine CHENAILLER
- Email: catherine.chenailler@chu-rouen.fr
- Phone: +3323288
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Pathology of the Locomotor System